S3 Ep38: Giri and Gomella on Fostering a New Framework for Genetic Testing Guidelines in Prostate Cancer
S3 Ep37: Tolaney Talks Tailored Treatment Strategies in HER2+ Breast Cancer
S3 Ep36: Herzog and Moore Mull Over the Role of Maintenance PARP Inhibition in Ovarian Cancer
S3 Ep35: Coleman and Slomovitz Continue the Discussion on Maintenance PARP Inhibition in Ovarian Cancer
S3 Ep34: GU Experts Review Treatment Options, Remaining Challenges, and Future Research in Penile Cancer
S3 Ep33: FDA Approval Insights: Avelumab in Metastatic Urothelial Carcinoma
S3 Ep32: Talking Tumors: Evaluating Early-Stage Breast Cancer Cases in the COVID-19 Era
S3 Ep31: Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy
S3 Ep30: Pegram Unpacks Pivotal Data in Breast Cancer
S3 Ep29: Research Reflections: Braunstein Breaks Down Top ASCO 2020 Abstracts in Myeloma
S3 Ep28: Markman and Monk Provide Perspective on the Utility of PARP Inhibitors in Ovarian Cancer
S3 Ep27: Dizon Discusses Elements of Sexual Health in Gynecologic Cancer
S3 Ep26: FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory MCL
S3 Ep25: DiNardo Discusses VIALE-A and Venetoclax Combo in AML
S3 Ep24: Talking KRAS-Targeted Therapy in NSCLC With Dr. Riess
S3 Ep23: Examining ADAURA and the Advantages of Adjuvant Osimertinib in EGFR+ NSCLC
S3 Ep22: FDA Approval Insights: Selpercatinib in RET+ NSCLC and Thyroid Cancers
S3 Ep21: Research Reflections: Sarcoma Experts Consider Emerging Evidence for Novel Combos
S3 Ep20: First of its Kind MMRF CureCloud Makes Way for Precision Medicine in Myeloma
S3 Ep19: Marvels in Medicine: Dr. Jordan on Undertaking an Unforeseen Career in Breast Cancer
S3 Ep18: FDA Approval Insights: Ramucirumab/Erlotinib in EGFR+ Metastatic NSCLC
S3 Ep17: Talking KRAS-Targeted Therapy in NSCLC With Dr. Drilon
S3 Ep16: Research Reflections: Weinberg Weighs in on Thought-Provoking Data in CRC
S3 Ep15: FDA Approval Insights: Olaparib in HRR-Mutant mCRPC
S3 Ep14: Marvels in Medicine: Vokes’s Venture to Bring Combined Modality Care to Patients With Cancer
S3 Ep13: Integrating Nutrition Into the Continuum of Cancer Care
S3 Ep12: FDA Approval Insights: Nivolumab/Ipilimumab in Advanced NSCLC
S3 Ep11: Marvels in Medicine: Dr. Gradishar on the Personal Pursuit of Precision Medicine in Breast Cancer
S3 Ep10: Research Reflections: Hamid Homes in on Key Efforts Made in Melanoma
S3 Ep9: Reviewing the Risk-Benefit Ratio of Adjuvant and Neoadjuvant Approaches in Melanoma
S3 Ep8: Chowdhary Covers Risk-Reducing Strategies and Recommendations During the COVID-19 Era
S3 Ep7: Marvels in Medicine: Dr. Karlan on Breaking Down Gender Barriers in Gynecologic Oncology
S3 Ep6: Dr. Burris and Dr. Graff Talk COVID-19 and Cancer Care, Telemedicine, and ASCO Initiatives
S3 Ep5: FDA Approval Insights: Subcutaneous Daratumumab in Multiple Myeloma
S3 Ep4: McGregor Details GU Treatment Guidelines During COVID-19 Pandemic
S3 Ep3: FDA Approval Insights: Olaparib/Bevacizumab in Advanced Ovarian Cancer
S3 Ep2: Talking Tumors: Exploring Management Strategies in Multiple Myeloma
S3 Ep1: Making Headway in GI Malignancies in Miami
S2 Ep50: The Uromigos Unveil Updates and Insights on the Impact of COVID-19 on GU Cancers
S2 Ep49: Marvels in Medicine: Gabriel Hortobagyi on Challenging Historical Dogmas in Breast Cancer
S2 Ep48: FDA Approval Insights: Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
S2 Ep47: Observing Optimal Treatment Strategies in Ovarian Cancer in Ohio
S2 Ep46: Talking Tumors: Treating With Immunotherapy and Targeted Therapy in Lung Cancer
S2 Ep45: Navigating Newfound GU Treatment Considerations in the Context of COVID-19
S2 Ep44: Physician and Patient Perspectives on Diagnosis and Treatment in Essential Thrombocythemia
S2 Ep43: Homing in on Clinical Advances in Hematologic Malignancies in Chicago
S2 Ep42: Gaining Ground in Genitourinary Malignancies in Nashville
S2 Ep41: Talking HER2-Targeted Therapy With Dr. Ajani
S2 Ep40: Talking HER2-Targeted Therapy With Dr. Chau
S2 Ep39: Talking HER2-Targeted Therapy With Dr. Marshall
next page